Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lorlatinib + chemotherapy
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lorlatinib + chemotherapy is a combination treatment regimen being investigated as an induction therapy for patients with resectable ALK-positive non-small cell lung cancer (NSCLC). Lorlatinib is a potent, third-generation, brain-penetrant small-molecule tyrosine kinase inhibitor (TKI) targeting ALK and ROS1, specifically designed to overcome resistance mutations that develop after treatment with earlier-generation TKIs like crizotinib or alectinib. In this clinical trial context sponsored by The First Affiliated Hospital of Guangzhou Medical University, lorlatinib is combined with standard chemotherapy to evaluate its efficacy in remodeling the tumor microenvironment and to identify potential primary resistance mechanisms using advanced genomic techniques like single-cell RNA sequencing and spatial transcriptomics.
- Brand names
- LorbrenaLorviqua
- Other names
- lorlatinib plus chemotherapy
02
Targets
ROS1 (Proto-oncogene tyrosine-protein kinase ROS)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)
Beyond the preview
Go deeper on lorlatinib + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lorlatinib + chemotherapy.